Loading organizations...
Loading organizations...
Helix is a technology company.
Helix develops integrated population genomics solutions that empower healthcare organizations, payers, and pharmaceutical companies to leverage genomic data. The company provides the infrastructure and tools necessary to incorporate genomics into clinical care, precision medicine initiatives, and therapeutic development. Its platform supports large-scale genetic sequencing and analysis, generating actionable insights for diagnostics, treatment, and population health management.
The company was founded in 2015. It emerged from an understanding of the immense potential of genomic information to transform medicine, but also the complexity and infrastructure challenges involved in bringing it to clinical practice. This led to the development of a unified platform designed to streamline the collection, processing, and interpretation of genomic data at scale for broad applications.
Helix serves a diverse client base including health systems, life science organizations, and public health entities. Its vision centers on enabling a future where genomic insights are seamlessly integrated across the healthcare continuum, facilitating a proactive and personalized approach to medical research, disease diagnosis, and preventive care for healthier populations.
Helix has raised $420.0M across 6 funding rounds.
Key people at Helix.
Helix was founded in 2015 by James Lu (CEO and co-founder).
Helix has raised $420.0M in total across 6 funding rounds.
Helix was founded in 2015 by James Lu (CEO and co-founder).
Helix has raised $420.0M in total across 6 funding rounds.
Helix's investors include DFJ Growth, Kleiner Perkins, Mayo Clinic, Temasek, Warburg Pincus, National Institutes of Health, Barry Schuler, Broadway Angels, DFJ, Peter Henry, Jay Flatley, Keith Stewart.
Helix refers to multiple technology companies, but the most prominent active player is Helix (helix.com), a genomics platform pioneering AI-driven solutions for healthcare. It builds an enterprise genomics platform that integrates genetic insights into health systems, payers, pharma, and life sciences, serving health systems, providers, life sciences organizations, and payers. The platform solves challenges in precision medicine by enabling genomic testing, research networks, clinical decision-making, and cost management—such as reducing healthcare spend through high-risk population identification and personalized care—while driving revenue via new genomic offerings and patient engagement.[2]
This positions Helix at the intersection of genomics and AI, transforming raw genetic data into actionable strategies for better outcomes and efficiency, with features like the Helix Research Network for discoveries, Precision Pathway for clinical insights, and Genomic Advantage for payers.[2]
Helix (helix.com) emerged as a leader in enterprise genomics, though specific founding details like year and founders are not detailed in available sources; it has built a robust network with over 15 HRN members and diverse patient cohorts committed to advancing precision medicine.[2] The company's idea stems from the need to scale genomics beyond isolated testing into everyday healthcare, fueled by advancements in AI and large-scale clinico-genomic data.[2]
Pivotal traction includes partnerships across health systems and life sciences, enabling collective genomic intelligence for real-world impact, such as streamlined clinical trials and population health initiatives.[2] (Note: An earlier Helix Software Company, founded in 1986 in New York, developed DOS/Windows utilities like memory managers licensed to Microsoft, but merged into Network Associates in 1997 and is defunct.[1])
Helix stands out in the genomics space through these key strengths:
These features prioritize scalability, actionable data, and cross-industry partnerships over standalone testing.
Helix rides the precision medicine trend, where AI and genomics converge to personalize healthcare amid rising data volumes and demands for value-based care. Timing is ideal as genomic sequencing costs plummet and regulations favor data-driven outcomes, with market forces like aging populations and chronic disease burdens amplifying demand for predictive tools.[2]
It influences the ecosystem by enabling health systems to expand capabilities, payers to cut costs, and pharma to streamline trials—creating network effects through shared cohorts and fueling broader adoption of genomic intelligence in routine care.[2] This positions Helix as a bridge between raw biotech data and operational healthcare tech.
Helix is poised to expand its platform with deeper AI integrations and larger cohorts, capitalizing on trends like multi-omics data and real-world evidence for drug development. Evolving regulations and payer incentives will likely boost adoption, potentially growing its influence through more HRN partnerships and global reach.[2]
As genomics becomes core to healthcare, Helix could redefine enterprise precision medicine, tying back to its mission of transforming genetic insights into scalable, revenue-generating strategies for a more efficient health ecosystem.[2]
Key people at Helix.
Helix has raised $420.0M across 6 funding rounds. Most recently, it raised $50.0M Series C in June 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 4, 2021 | $50.0M Series C | DFJ Growth, Kleiner Perkins, Mayo Clinic, Temasek, Warburg Pincus | |
| Jul 31, 2020 | $33.0M Grant | National Institutes of Health | |
| Feb 1, 2018 | $200.0M Series B | Barry Schuler | Broadway Angels, DFJ, Peter Henry, Jay Flatley, Kleiner Perkins, Keith Stewart, Sutter Hill Ventures, Warburg Pincus |
| Dec 21, 2015 | $29.0M Series B | Nina Yang, Temasek | Borealis Ventures, DFJ, Far East Ventures, Obvious Ventures, South Park Ventures |
| Aug 18, 2015 | $100.0M Other Equity | Mayo Clinic, Sutter Hill Ventures, Warburg Pincus | |
| May 1, 2014 | $8.0M Series A | Steve Jurvetson | Future Ventures, Evan Williams, Andreessen Horowitz, Jesse Devitte, Google Ventures |